Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Edesa Biotech, Inc. Common Shares

EDSA

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Last trade $2.04
Day change +$0.15 (+7.94%)
Day range $1.85 – $2.04
Volume 247,827
Market cap $18M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$18.22M
Price / earnings
—
Price / book
2.07×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.54×

Profitability

Earnings per share
-$1.46
Return on assets
-110.85%
Return on equity
-160.05%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.76×
Quick ratio
2.76×
Cash ratio
2.64×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.91M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for EDSA, quarterly periods
Line itemQ3 FY2026 Jun 30, 2026Q2 FY2026 Mar 31, 2026Q1 FY2026 Dec 31, 2025Q4 FY2025 Sep 30, 2025Q3 FY2025 Jun 30, 2025Q2 FY2025 Mar 31, 2025Q1 FY2025 Dec 31, 2024Q4 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.56M$1.53M$1.22M$1.24M$964.68K$1.15M$878.87K$900.53K
Research and development$3.96M$2.77M$1.12M$1.23M$939.07K$484.31K$1.02M$103.87K
Total operating expenses$5.52M$4.3M$2.34M$2.47M$1.9M$1.64M$1.9M$1M
Operating income-$5.52M-$4.3M-$2.34M-$2.47M-$1.9M-$1.64M-$1.9M-$1M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$5.41M-$4.22M-$2.25M-$2.23M-$1.75M-$1.59M-$1.62M-$962.05K
Income taxes$0$800$0$0$0$800$0$0
Net income-$5.41M-$4.22M-$2.25M-$2.23M-$1.75M-$1.59M-$1.62M-$962.05K
Net income attributable to common shareholders-$5.41M-$4.22M-$2.25M-$2.23M-$1.75M-$1.59M-$1.62M-$962.05K
EBITDA-$5.49M-$4.27M-$2.32M-$2.44M-$1.88M-$1.61M-$1.86M-$960.19K
Basic earnings per share-$0.60-$0.49-$0.28-$0.32-$0.25-$0.30-$0.48-$0.30
Diluted earnings per share-$0.60-$0.49-$0.28-$0.32-$0.25-$0.30-$0.48-$0.30

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Acute Respiratory Distress Syndrome Market to Grow Steadily at a 3.8% CAGR Through 2036, Supported by Emerging ARDS Therapies | DelveInsight

The ARDS market is projected to grow at a 3.8% CAGR through 2036, valued at USD 1.7 billion in 2025 across seven major markets. Growth is driven by rising ARDS incidence, advancements in critical care management, and the entry of emerging therapies including MultiStem, ExoFlo, ThyrOxy, and Gelsolin. Currently, no FDA-approved therapies specifically treat ARDS, with mechanical ventilation remaining the standard care approach.

Benzinga

Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Shares of ReShape Lifesciences Inc. (NASDAQ: RSLS) rose sharply in pre-market trading after the company said it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX. ReShape Lifesciences shares jumped 44.6% to $0.3630 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers RiskOn International, Inc. (NASDAQ: ROI) shares rose 84.3% to $0.2678 in pre-market trading after declining 9% on Tuesday. Innovative International Acquisition Corp. (NASDAQ: IOAC) shares rose 28.6% to $10.93 in pre-market trading. C4 Therapeutics, Inc. (NASDAQ: CCCC) gained 28.6% to $3.01 in pre-market trading after the company announced positive data from CFT7455 Phase 1 trial in relapsed/refractory multiple myeloma. Stifel upgraded C4 Therapeutics from Hold to Buy and raised the price target from $2 to $12. Mynaric AG (NASDAQ: MYNA) shares surged 16.9% to $5.60 in pre-market trading after the company received a $33 million order from Northrop Grumman. MyMD Pharmaceuticals, Inc. (NASDAQ:

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 11, 20231-for-7reverse split
May 7, 20181-for-7reverse split